DK0627221T3 - Substans P antagonister til behandling af emesis - Google Patents

Substans P antagonister til behandling af emesis

Info

Publication number
DK0627221T3
DK0627221T3 DK94303467T DK94303467T DK0627221T3 DK 0627221 T3 DK0627221 T3 DK 0627221T3 DK 94303467 T DK94303467 T DK 94303467T DK 94303467 T DK94303467 T DK 94303467T DK 0627221 T3 DK0627221 T3 DK 0627221T3
Authority
DK
Denmark
Prior art keywords
emesis
antagonists
substance
treatment
derivatives
Prior art date
Application number
DK94303467T
Other languages
Danish (da)
English (en)
Inventor
Manoj C Desai
Iii John A Lowe
John W Watson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0627221T3 publication Critical patent/DK0627221T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK94303467T 1993-06-04 1994-05-16 Substans P antagonister til behandling af emesis DK0627221T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (1)

Publication Number Publication Date
DK0627221T3 true DK0627221T3 (da) 2002-02-11

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94303467T DK0627221T3 (da) 1993-06-04 1994-05-16 Substans P antagonister til behandling af emesis

Country Status (19)

Country Link
US (1) US5393762A (cs)
EP (1) EP0627221B1 (cs)
JP (1) JP2671972B2 (cs)
KR (1) KR100190729B1 (cs)
CN (1) CN1100535C (cs)
AT (1) ATE209490T1 (cs)
AU (1) AU666077B2 (cs)
CA (1) CA2124990C (cs)
DE (1) DE69429208T2 (cs)
DK (1) DK0627221T3 (cs)
ES (1) ES2164088T3 (cs)
HU (1) HU222243B1 (cs)
IL (1) IL109802A (cs)
MY (1) MY115310A (cs)
NZ (1) NZ260674A (cs)
PT (1) PT627221E (cs)
RU (1) RU2135179C1 (cs)
TW (1) TW318791B (cs)
ZA (1) ZA943896B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
EP0589924B1 (en) * 1991-06-20 1996-09-04 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP0533280B2 (en) 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
KR19980703354A (ko) * 1995-03-27 1998-10-15 나카토미히로타카 피페리딘 유도체
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
JP2002506459A (ja) * 1997-06-27 2002-02-26 メルク シヤープ エンド ドーム リミテツド 置換された３−（ベンジルアミノ）ピペリジン誘導体およびその治療薬としての使用
CA2352612A1 (en) * 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
RU2197961C2 (ru) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Средство для профилактики и купирования тошноты и рвоты
RU2183118C1 (ru) * 2001-07-12 2002-06-10 Государственный научный центр РФ Институт медико-биологических проблем РАН Способ профилактики вестибуловегетативных расстройств у человека в условиях воздействий, вызывающих укачивание
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
PT1713504T (pt) * 2004-01-30 2017-08-29 Zoetis Services Llc Conservantes antimicrobianos para obter uma formulação multidose utilizando beta-ciclodextrinas para formas galénicas líquidas
KR100880391B1 (ko) * 2004-01-30 2009-01-30 화이자 프로덕츠 인크. 마취 회복 개선용 ｎｋ-1 수용체 길항제
EP1713801B1 (en) * 2004-02-02 2007-12-12 Pfizer Products Incorporated Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
HUT62891A (en) * 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
PL167568B1 (pl) * 1990-07-23 1995-09-30 Pfizer Sposób wytwarzania nowych pochodnych chinuklidyny PL PL
DE69109125T2 (de) * 1990-09-28 1995-09-28 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
CA2100163A1 (en) * 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
CA2105302C (en) * 1991-03-01 1996-11-12 Pfizer Limited 1-azabicyclo¬3.2.2.|nonan-3-amine derivatives
BR9205807A (pt) * 1991-03-26 1994-06-28 Pfizer Preparação estéreo-seletiva de piperidinas substituidas
PL170513B1 (en) * 1991-05-22 1996-12-31 Pfizer Method of obtaining novel derivatives of 3-amino quinuclidine
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
EP0589924B1 (en) * 1991-06-20 1996-09-04 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (cs) * 1991-06-21 1993-03-21 Pfizer
EP0533280B2 (en) * 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
DE69232588T2 (de) * 1991-09-26 2002-08-22 Pfizer Inc., New York Kondensierte trizyklische, stickstoffenthaltende Verbindungen als Substanz P Rezeptor Antagonisten
ATE161821T1 (de) * 1991-11-12 1998-01-15 Pfizer Azyklische ethylendiaminderivate als 'substance p rezeptor' antagonisten
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
DE69328975T2 (de) * 1992-12-10 2000-11-09 Pfizer Inc., New York Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
WO2000010073A1 (en) * 1998-08-14 2000-02-24 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
AU666077B2 (en) 1996-01-25
RU94020410A (ru) 1996-05-10
IL109802A0 (en) 1994-08-26
ES2164088T3 (es) 2002-02-16
NZ260674A (en) 2000-07-28
ATE209490T1 (de) 2001-12-15
EP0627221A3 (en) 1995-08-02
EP0627221A2 (en) 1994-12-07
PT627221E (pt) 2002-04-29
DE69429208T2 (de) 2002-05-23
RU2135179C1 (ru) 1999-08-27
JPH0753362A (ja) 1995-02-28
HU9401676D0 (en) 1994-09-28
EP0627221B1 (en) 2001-11-28
DE69429208D1 (de) 2002-01-10
MY115310A (en) 2003-05-31
AU6452194A (en) 1994-12-15
TW318791B (cs) 1997-11-01
CN1121806A (zh) 1996-05-08
CA2124990C (en) 1999-04-20
KR100190729B1 (ko) 1999-06-01
US5393762A (en) 1995-02-28
IL109802A (en) 2002-04-21
HUT71550A (en) 1995-12-28
KR950000144A (ko) 1995-01-03
CN1100535C (zh) 2003-02-05
JP2671972B2 (ja) 1997-11-05
HU222243B1 (hu) 2003-05-28
ZA943896B (en) 1995-12-04

Similar Documents

Publication Publication Date Title
DK0627221T3 (da) Substans P antagonister til behandling af emesis
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
ATE207897T1 (de) Piperidinderivate als neurokininantagonisten
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69133397D1 (de) Benzoylderivate
GB9406857D0 (en) Improvements in or relating to organic compounds
MX9200294A (es) Inhibidores de cinasa de adenosina
ATE148114T1 (de) Fluor substituierte benzocycloheptapyridine, zusammensetzungen und verfahren zur verwendung derselben als antihistaminische verbindungen
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
DK0701546T3 (da) Aromatiske acetylchlolinesteraseinhibitorer
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DK0684951T3 (da) Silylerede acetylcholinesterase-inhibitorer
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
EA199800535A1 (ru) Способ лечения боли
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
DK0821955T3 (da) Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis